Outcomes

The evidence on DSIP (Delta Sleep-Inducing Peptide) outcomes is extremely limited, with only one directly relevant study identified in the literature.

Motor Function Recovery After Stroke
One study (PMID: 34500605) reported that DSIP recovered motor function in Sprague-Dawley rats following focal stroke. However, this is a single animal study with no human data available, representing very preliminary evidence.

Sleep-Related Applications
While one study mentions "DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models" (PMID: 39444618), the specific outcomes and measurable results are not detailed in the available evidence. This represents another animal model study with limited applicability to human outcomes.

Blood-Brain Barrier Penetration
There is mention of DSIP crossing the blood-brain barrier (PMID: 39444618), which could be relevant for central nervous system applications, but specific pharmacokinetic data or biomarker changes are not provided in the available evidence.

Strength of Evidence
The evidence for DSIP outcomes is notably weak. No human clinical trials were identified, and the available data consists of isolated animal studies with minimal detail on specific measurable outcomes. The lack of systematic clinical research, absence of biomarker data, standardized outcome measures, or symptom improvement scales in human subjects severely limits any conclusions about DSIP's therapeutic efficacy.

This information is for research purposes only and should not be used for medical decision-making without consulting healthcare professionals.

DSIP

Member access required